HELLO! speaks to leading experts about the simple mistakes that can hold back results of weight loss injections or lead to unwanted side effects. See details.

Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech risks. Learn why VKTX stock is a strong buy.

Recent advancements in medical therapy for heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) include 3 classes of therapy—sodium glucose cotransporter ...

A team of researchers from the University of Minnesota Twin Cities College of Science and Engineering and the University of Houston's Cullen College of Engineering has discovered and measured the ...

Metsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global Phase 3 program in 2025.

Vertanical’s cannabis-based pain reliever, VER-01, has shown superiority over opioids in a Phase III trial.

A team of researchers from the University of Minnesota Twin Cities College of Science and Engineering and the University of Houston’s Cullen College of Engineering has discovered and measured the ...

At World Sleep 2025, a discussion group examined the emerging role of GLP-1 receptor agonists in obstructive sleep apnea (OSA), particularly tirzepatide (Zepbound), which late last year became the ...

Of all the possible side effects that come with taking a GLP-1, losing your hair is perhaps one of the scariest. The good news is this hair loss is typically temporary and will resolve over time. To ...